{"id":"W4386447675","doi":"10.1200/jco.22.02906","title":"Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Eisai; G1 Therapeutics; MacroGenics; AstraZeneca España; Amgen; Radius Health; Syndax Pharmaceuticals; BeiGene; Clovis Oncology; Pfizer; Incyte; NuCana; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Taiho Pharmaceutical; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Plexxikon; Seagen; Relay Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Endometrial cancer; Chemotherapy; Oncology; Maintenance therapy; Internal medicine; Gynecologic cancer; Cancer; Gynecology; Ovarian cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008531977,0.0003439418,0.001354226,0.0003627538,0.0001425032,0.0002953148,0.0004165523,0.0003717777,0.002053832],"category_scores_gemma":[0.0008121151,0.0001577007,0.0005311992,0.0002001205,0.0004482711,0.0003853451,0.0002626815,0.0006336207,0.0002372871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003062153,"about_ca_system_score_gemma":0.0002931631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002064494,"about_ca_topic_score_gemma":0.001070722,"domain_scores_codex":[0.9997249,0.0001302362,0.00002565405,0.00004499139,0.00003940224,0.00003481343],"domain_scores_gemma":[0.9996049,0.0001118634,0.0001211507,0.00002873781,0.00001304167,0.0001203092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4401886,0.007312938,0.01738146,0.003120527,0.001335777,0.0003849397,0.0002520419,0.002093525,0.02058748,0.0003890496,0.002433127,0.5045206],"study_design_scores_gemma":[0.3568174,0.5415903,0.07539466,0.0007173826,0.001492729,0.001214967,0.0001613555,0.0032917,0.008224546,0.0005504086,0.01048055,0.0000640488],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826385,0.01439512,0.0004629769,0.0002518314,0.0001072065,0.0005382029,0.0002269648,0.00008453787,0.001294639],"genre_scores_gemma":[0.9945183,0.003352489,0.0005780956,0.0001938109,0.00008599913,0.0003639601,0.0001913156,0.000005261933,0.000710707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002053832,"threshold_uncertainty_score":0.006870747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08886164544139567,"score_gpt":0.4607676338415168,"score_spread":0.3719059884001211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}